search
Back to results

The IM-ZBULLE Study : " Z-track " and " Airlock " Techniques During Intramuscular Injection of Haloperidol Decanoate (IM-ZBULLE)

Primary Purpose

Schizophrenia; Psychosis

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Intramuscular injection of Haloperidol decanoate using the "Z-track" and "Airlock" techniques
Intramuscular injection of Haloperidol decanoate using standard techniques
Sponsored by
Centre Hospitalier St Anne
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Schizophrenia; Psychosis focused on measuring Schizophrenia, Haloperidol decanoate

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adult ; having an outpatient treatment in a Mental Health Community Center ("Centre Médico-Psychologique" CMP in french) ; with an CIM-10 diagnosis between F20-F29 (Schizophrenia, schizotypal disorder and delusional disorders); communicative and able to give free and informed consent to the study; prescribed Haloperidol decanoate; covered by the french social security Exclusion Criteria: Minor ; pregnant women ; with insufficient understanding of the French language to understand the VAS; suffering from any of the following known somatic comorbidity : coagulation disorder, leucopenia, immunosuppression; currently prescribed treatment: immunosuppressant, anticoagulant, antibiotic, antiretroviral, other products administered by IMI at dorsogluteal injection sites (antibiotic therapy, hormone therapy, vitamin therapy).

Sites / Locations

  • Rayan BCHINI

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Intramuscular injection of Haloperidol decanoate using the "Z-track" and "Airlock" techniques

Control arm, Intramuscular injection as usual

Arm Description

Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the "Z-track" and "Airlock" techniques.

Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique

Outcomes

Primary Outcome Measures

pain reduction
To evaluate the efficacy of combining the "Z-track" and "Airlock" techniques concerning reducing pain in adult patients treated with Haloperidol decanoate. The primary outcome measure is pain reduction, assessed using a millimeter-scale visual analogic scale (VAS) to measure pain perceived by the patient 5 minutes after the treatment. The score is between 0 (minimum) and 10 (maximum) centimeters. The higher the score, the worse the result.

Secondary Outcome Measures

Drug leakage reduction
To measure the loss (leakage) of active product when the needle is withdrawn : The outcome measure is a reduction in the loss of active product by assessing the diameter (using a millimeter scale) of active product that flow back through the puncture site using an absorbent pad.
Impact of the injection
To measure the impact of combining the "Z-track" and "Airlock" techniques on potential complications related to treatment : The outcome measure is the reduction in signs of secondary complications, as measured by a pre- and post-injection clinical examination and a phone call to the patient between Day 1 and Day 3.
Improving participants satisfaction
To measure overall patient satisfaction with the combination of "Z-track" and "Airlock" intramuscular injection techniques. The outcome measure is participant satisfaction, assessed using Attkisson's CSQ-8 questionnaire. This scale comprises 8 questions. Depending on the answer, each question awards 1 to 4 points. The score is therefore between 8 (minimum) and 32 (maximum) points. The higher the score, the better the result.
Improving the therapeutic alliance
To measure therapeutic alliance during follow-up :The outcome measure is the overall therapeutic alliance score, using the Working Alliance Inventory (WAI) scale before and after intervention. This scale comprises 12 questions. Each question awards 1 to 5 points, depending on the answer. The score is between 12 (minimum) and 60 (maximum) points. The higher the score, the better the result.
Identifying the obstacles and levers to changing practices
To identify the levers and obstacles to nurses' change of practice : The outcome measure is the identification of levers and obstacles to change in professional practice among psychiatric nurses, by means of a complementary qualitative descriptive study.

Full Information

First Posted
July 18, 2023
Last Updated
August 21, 2023
Sponsor
Centre Hospitalier St Anne
Collaborators
Groupe Hospitalier Paul Guiraud, Etablissement Public de Santé Barthélemy Durand
search

1. Study Identification

Unique Protocol Identification Number
NCT05995457
Brief Title
The IM-ZBULLE Study : " Z-track " and " Airlock " Techniques During Intramuscular Injection of Haloperidol Decanoate
Acronym
IM-ZBULLE
Official Title
Efficacy of the Combination of " Z-track " and " Airlock " Techniques During Intramuscular Injection of Haloperidol Decanoate in Adult Patients With Schizophrenic or Related Disorder : A Multicenter Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2023 (Anticipated)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
November 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier St Anne
Collaborators
Groupe Hospitalier Paul Guiraud, Etablissement Public de Santé Barthélemy Durand

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Intramuscular injection (IMI) is the process of administering a drug treatment into muscle tissue. The transmission of skills in this care practice is essentially based on the experience of peers. In France, there are no official guidelines for this technical procedure. Haloperidol decanoate is widely used in psychiatry. This long-acting antipsychotic treatment considerably reduces the risk of relapse and hospitalization. It is administered by IMI. This treatment is invasive, painful and risks complications for the patient. Nurses must ensure that the treatment is as painless as possible, and adapt their practice in line with current recommendations. Among the various IMI techniques available, the "Z-track" and the "Airlock" limit leakage into subcutaneous tissues when the needle is withdrawn, by locking the active product into the muscular tissues. According to an exploratory study (n=303), 73% of nurses observe active product leakage after injections, and 89% of nurses are not familiar with either the "Z-track" or "Airlock" techniques. Many foreign studies have been carried out to demonstrate the relevance of these techniques, particularly in terms of pain reduction during treatment, but the results have yet to be confirmed. The investigators hypothesize that the combined use of the "Z-track" and "Airlock" techniques during intramuscular injection of Haloperidol decanoate is more effective in reducing patient pain than usual practice.
Detailed Description
This is a multicenter, prospective, randomized, double-blind, controlled, study in 2 parallel groups. Experimental and control administration protocols will be standardized to harmonize injection practices between the different nurses providing care, and to control some variables. Nurses will have been trained in these protocols and in experimental injection techniques. The experimental group will be offered an intramuscular injection using the "Z-track" and "Airlock" techniques, while the control group will have an "usual" injection. An intermediate analysis of futility and efficacy is planned once 50% of the planned sample has completed the study. The object of the research is the intramuscular injection procedure - Product injected: haloperidol decanoate (Haldol Decanoas®).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia; Psychosis
Keywords
Schizophrenia, Haloperidol decanoate

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
Advanced practice nurses (APNs) will carry out clinical examinations before and after the treatment. They will not be present during the treatment, and the patient will not know the technique used, in order to ensure a double-blind evaluation. Only the nurses performing the injection will be aware of the technique used (experimental or control).
Allocation
Randomized
Enrollment
84 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intramuscular injection of Haloperidol decanoate using the "Z-track" and "Airlock" techniques
Arm Type
Experimental
Arm Description
Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the "Z-track" and "Airlock" techniques.
Arm Title
Control arm, Intramuscular injection as usual
Arm Type
Other
Arm Description
Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique
Intervention Type
Other
Intervention Name(s)
Intramuscular injection of Haloperidol decanoate using the "Z-track" and "Airlock" techniques
Intervention Description
Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the "Z-track" and "Airlock" techniques
Intervention Type
Other
Intervention Name(s)
Intramuscular injection of Haloperidol decanoate using standard techniques
Intervention Description
Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique.
Primary Outcome Measure Information:
Title
pain reduction
Description
To evaluate the efficacy of combining the "Z-track" and "Airlock" techniques concerning reducing pain in adult patients treated with Haloperidol decanoate. The primary outcome measure is pain reduction, assessed using a millimeter-scale visual analogic scale (VAS) to measure pain perceived by the patient 5 minutes after the treatment. The score is between 0 (minimum) and 10 (maximum) centimeters. The higher the score, the worse the result.
Time Frame
Day 0 intervention day T
Secondary Outcome Measure Information:
Title
Drug leakage reduction
Description
To measure the loss (leakage) of active product when the needle is withdrawn : The outcome measure is a reduction in the loss of active product by assessing the diameter (using a millimeter scale) of active product that flow back through the puncture site using an absorbent pad.
Time Frame
Day 0 intervention day
Title
Impact of the injection
Description
To measure the impact of combining the "Z-track" and "Airlock" techniques on potential complications related to treatment : The outcome measure is the reduction in signs of secondary complications, as measured by a pre- and post-injection clinical examination and a phone call to the patient between Day 1 and Day 3.
Time Frame
Day 0 to Day 3
Title
Improving participants satisfaction
Description
To measure overall patient satisfaction with the combination of "Z-track" and "Airlock" intramuscular injection techniques. The outcome measure is participant satisfaction, assessed using Attkisson's CSQ-8 questionnaire. This scale comprises 8 questions. Depending on the answer, each question awards 1 to 4 points. The score is therefore between 8 (minimum) and 32 (maximum) points. The higher the score, the better the result.
Time Frame
Day 14 or Day 21 or Day 28 depending to the frequency established by the prescription1
Title
Improving the therapeutic alliance
Description
To measure therapeutic alliance during follow-up :The outcome measure is the overall therapeutic alliance score, using the Working Alliance Inventory (WAI) scale before and after intervention. This scale comprises 12 questions. Each question awards 1 to 5 points, depending on the answer. The score is between 12 (minimum) and 60 (maximum) points. The higher the score, the better the result.
Time Frame
Day 0 (intervention day) and Day 14 or Day 21 or Day 28 depending to the frequency established by the prescription
Title
Identifying the obstacles and levers to changing practices
Description
To identify the levers and obstacles to nurses' change of practice : The outcome measure is the identification of levers and obstacles to change in professional practice among psychiatric nurses, by means of a complementary qualitative descriptive study.
Time Frame
During 14 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult ; having an outpatient treatment in a Mental Health Community Center ("Centre Médico-Psychologique" CMP in french) ; with an CIM-10 diagnosis between F20-F29 (Schizophrenia, schizotypal disorder and delusional disorders); communicative and able to give free and informed consent to the study; prescribed Haloperidol decanoate; covered by the french social security Exclusion Criteria: Minor ; pregnant women ; with insufficient understanding of the French language to understand the VAS; suffering from any of the following known somatic comorbidity : coagulation disorder, leucopenia, immunosuppression; currently prescribed treatment: immunosuppressant, anticoagulant, antibiotic, antiretroviral, other products administered by IMI at dorsogluteal injection sites (antibiotic therapy, hormone therapy, vitamin therapy).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rayan BCHINI, IPA
Phone
33 1 42 11 75 90
Email
rayan.francoisbchini@gh-paulguiraud.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Cécile BERGOT
Email
C.BERGOT@ghu-paris.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rayan BCHINI
Organizational Affiliation
GHU Paris Psychiatrie & Neurosciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rayan BCHINI
City
Villejuif
ZIP/Postal Code
94800
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rayan BCHINI, Master 2 IPA
Phone
+33142117590
Email
rayan.francoisbchini@gh-paulguiraud.fr

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
37328226
Citation
Bchini R, Goutte N. [Evidence-based practice and nursing: intramuscular injection in psychiatry]. Soins Psychiatr. 2023 May-Jun;44(346):21-26. doi: 10.1016/j.spsy.2023.04.006. Epub 2023 Jun 7. French.
Results Reference
background
PubMed Identifier
10718876
Citation
Rodger MA, King L. Drawing up and administering intramuscular injections: a review of the literature. J Adv Nurs. 2000 Mar;31(3):574-82. doi: 10.1046/j.1365-2648.2000.01312.x.
Results Reference
background
PubMed Identifier
16393108
Citation
Wynaden D, Landsborough I, Chapman R, McGowan S, Lapsley J, Finn M. Establishing best practice guidelines for administration of intra muscular injections in the adult: a systematic review of the literature. Contemp Nurse. 2005 Dec;20(2):267-77. doi: 10.5172/conu.20.2.267.
Results Reference
background
PubMed Identifier
31452229
Citation
Sanlialp Zeyrek A, Takmak S, Kurban NK, Arslan S. Systematic review and meta-analysis: Physical-procedural interventions used to reduce pain during intramuscular injections in adults. J Adv Nurs. 2019 Dec;75(12):3346-3361. doi: 10.1111/jan.14183. Epub 2019 Sep 13.
Results Reference
background
PubMed Identifier
3636818
Citation
Keen MF. Comparison of intramuscular injection techniques to reduce site discomfort and lesions. Nurs Res. 1986 Jul-Aug;35(4):207-10.
Results Reference
background
PubMed Identifier
3230758
Citation
Kim KS. [Comparison of two intramuscular injection technics on the severity of discomfort and lesions at the injection site]. Kanho Hakhoe Chi. 1988 Dec;18(3):257-68. doi: 10.4040/jnas.1988.18.3.257. Korean.
Results Reference
background
PubMed Identifier
7644369
Citation
Quartermaine S, Taylor R. A comparative study of depot injection techniques. Nurs Times. 1995 Jul 26-Aug 1;91(30):36-9.
Results Reference
background
PubMed Identifier
9732632
Citation
Mac Gabhann L. A comparison of two depot injection techniques. Nurs Stand. 1998 Jun 3-9;12(37):39-41. doi: 10.7748/ns1998.06.12.37.39.c2512.
Results Reference
background
PubMed Identifier
26905354
Citation
Yilmaz DK, Dikmen Y, Kokturk F, Dedeoglu Y. The effect of air-lock technique on pain at the site of intramuscular injection. Saudi Med J. 2016 Mar;37(3):304-8. doi: 10.15537/smj.2016.3.13113.
Results Reference
background
PubMed Identifier
25039702
Citation
Kara D, Yapucu Gunes U. The effect on pain of three different methods of intramuscular injection: A randomized controlled trial. Int J Nurs Pract. 2016 Apr;22(2):152-9. doi: 10.1111/ijn.12358. Epub 2014 Jul 11.
Results Reference
background
PubMed Identifier
33939726
Citation
Ayinde O, Hayward RS, Ross JDC. The effect of intramuscular injection technique on injection associated pain; a systematic review and meta-analysis. PLoS One. 2021 May 3;16(5):e0250883. doi: 10.1371/journal.pone.0250883. eCollection 2021.
Results Reference
background
PubMed Identifier
33714700
Citation
Heshmatifar N, Salari M, Rad M, Afshari Saleh T, Borzoee F, Rastaghi S. A New Approach on the pain management of intramuscular injection: A Triple-Blind Randomized Clinical Trial. Pain Manag Nurs. 2022 Jun;23(3):353-358. doi: 10.1016/j.pmn.2021.01.010. Epub 2021 Mar 11.
Results Reference
background
PubMed Identifier
11775044
Citation
Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry. 2001 Nov;62(11):855-9. doi: 10.4088/jcp.v62n1104.
Results Reference
background

Learn more about this trial

The IM-ZBULLE Study : " Z-track " and " Airlock " Techniques During Intramuscular Injection of Haloperidol Decanoate

We'll reach out to this number within 24 hrs